ES2696074T3 - Tratamiento del cáncer de mama - Google Patents

Tratamiento del cáncer de mama Download PDF

Info

Publication number
ES2696074T3
ES2696074T3 ES12846720T ES12846720T ES2696074T3 ES 2696074 T3 ES2696074 T3 ES 2696074T3 ES 12846720 T ES12846720 T ES 12846720T ES 12846720 T ES12846720 T ES 12846720T ES 2696074 T3 ES2696074 T3 ES 2696074T3
Authority
ES
Spain
Prior art keywords
trip trip
tio
tra
breast cancer
amen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846720T
Other languages
English (en)
Spanish (es)
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2696074(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics LLC, University of Colorado System, University of Colorado Colorado Springs filed Critical Medivation Prostate Therapeutics LLC
Application granted granted Critical
Publication of ES2696074T3 publication Critical patent/ES2696074T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12846720T 2011-07-29 2012-07-27 Tratamiento del cáncer de mama Active ES2696074T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
ES2696074T3 true ES2696074T3 (es) 2019-01-14

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12846720T Active ES2696074T3 (es) 2011-07-29 2012-07-27 Tratamiento del cáncer de mama

Country Status (18)

Country Link
US (4) US9517229B2 (https=)
EP (4) EP3430907A1 (https=)
JP (2) JP6158180B2 (https=)
KR (1) KR101923250B1 (https=)
CN (1) CN103997894B (https=)
BR (1) BR112014002200A2 (https=)
CA (1) CA2843417C (https=)
CY (1) CY1121038T1 (https=)
DK (1) DK2739153T3 (https=)
EA (1) EA028452B1 (https=)
ES (1) ES2696074T3 (https=)
HU (1) HUE040524T2 (https=)
MX (1) MX359664B (https=)
PH (1) PH12014500248B1 (https=)
PL (1) PL2739153T3 (https=)
PT (1) PT2739153T (https=)
SI (1) SI2739153T1 (https=)
WO (1) WO2013066440A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) * 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
NZ594741A (en) * 2009-02-24 2014-03-28 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
EP3791724A1 (en) 2021-03-17
PT2739153T (pt) 2018-11-28
PH12014500248B1 (en) 2018-08-31
WO2013066440A1 (en) 2013-05-10
EA028452B1 (ru) 2017-11-30
JP2014524934A (ja) 2014-09-25
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP6158180B2 (ja) 2017-07-05
JP2017141269A (ja) 2017-08-17
EP3430907A1 (en) 2019-01-23
EA201400178A1 (ru) 2014-11-28
PH12014500248A1 (en) 2014-03-17
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
DK2739153T3 (en) 2018-12-03
HK1201413A1 (en) 2015-09-04
EP2739153B1 (en) 2018-08-22
CN103997894B (zh) 2016-08-24
HUE040524T2 (hu) 2019-03-28
SI2739153T1 (sl) 2018-12-31
CA2843417A1 (en) 2013-05-10
BR112014002200A2 (pt) 2017-03-07
US10111861B2 (en) 2018-10-30
US20140296312A1 (en) 2014-10-02
PL2739153T3 (pl) 2019-04-30
KR101923250B1 (ko) 2018-11-28
KR20140107174A (ko) 2014-09-04
EP3610731A1 (en) 2020-02-19
US20170087132A1 (en) 2017-03-30
CN103997894A (zh) 2014-08-20
WO2013066440A9 (en) 2013-07-18
CA2843417C (en) 2018-08-21
EP2739153A4 (en) 2015-03-11
MX2014001218A (es) 2014-08-22
EP2739153A1 (en) 2014-06-11
US20210069154A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
ES2696074T3 (es) Tratamiento del cáncer de mama
ES2808056T3 (es) Sincronización entre secuencias de imágenes del corazón adquiridas a diferentes frecuencias cardiacas
Quak et al. F18-choline, a novel PET tracer for parathyroid adenoma?
Sankar et al. Oral complications from oropharyngeal cancer therapy
JP2019536805A5 (https=)
Beaumont et al. Isotope analysis of incremental human dentine: towards higher temporal resolution
RU2018142394A (ru) Композиции и способы для лечения нейтропении
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
JP2019517498A5 (https=)
Baldari et al. Management of metastatic castration-resistant prostate cancer: a focus on radium-223: opinions and suggestions from an expert multidisciplinary panel
US10720228B2 (en) Method and system for testing of active molecules using molecular simulation of skin membrane
Murray et al. A new species in the Hipposideros bicolor group (Chiroptera: Hipposideridae) from Peninsular Malaysia
Nave et al. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar.
Yusoff et al. Pentadbiran Undang-Undang Harta Pusaka Mualaf Di Malaysia: Satu Sorotan Literatur: Administration of Mualaf Inheritance at Wilayah Persekutuan: A Literature Highlights
Fayez et al. Intranasal radioiodinated ferulic acid polymeric micelles as the first nuclear medicine imaging probe for ETRA brain receptor
Bur et al. Effect of exercise on transdermal nicotine release in healthy habitual smokers.
Herman Progress and dilemma of contemporary clinical pharmacology.
Jeremić et al. Comparison of three methods used for measurement of radioiodine fixation in thyroid gland of mice
Welling The Drug Development Process: Increasing Efficiency and Cost-Effectiveness
Mhingo Australian vaccine could put stop to malaria
Barua et al. Federal Delays in Approving New Medicines 2013
Dumontet et al. P-479 Expression of class III beta tubulin is predictive of patientoutcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
Serafim et al. Relationship between mandibular growth and skeletal maturation in young melanodermic Brazilian women
Woloshun Select Amino Acids Enhance or Reduce Iron Absorption Via DMT1 Trafficking for Treatment of Iron-Deficiency Anemia and Iron-Overload Disorders
Williamson et al. Vitamin B12 improves skeletal muscle mitochondrial biology in aged mice